Provided are methods and combinations for treating and/or preventing dry eye disease (DED) by treating a subject in need thereof with a combination of at least one parasympathetic agent at least one anti-sympathetic effective to treat said dry eye disease.

Provided are methods and combinations for treating and/or preventing dry eye disease (DED) by treating a subject in need thereof with a combination of at least one parasympathetic agent at least one anti-sympathetic effective to treat said dry eye disease.

Provided are methods and combinations for treating and/or preventing dry eye disease (DED) by treating a subject in need thereof with a combination of at least one parasympathetic agent at least one anti-sympathetic effective to treat said dry eye disease.

The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: ##STR00001## wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R.sub.1 and R.sub.2 are independently H— or alkyl; R.sub.3 is H—, alkyl or aralkyl; and R.sub.4 is H— or aryl.

The present disclosure provides a compound represented by Formula (I) and a pharmaceutically acceptable salt which are effective as a dopamine reuptake inhibitor and a method of using the compound: ##STR00001## wherein X is independently halo, alkyl, alkoxy or nitro; m is 0, 1, 2, 3 or 4; n is 1 or 2; R.sub.1 and R.sub.2 are independently H— or alkyl; R.sub.3 is H—, alkyl or aralkyl; and R.sub.4 is H— or aryl.

Disclosed are compounds, for example, compounds of formula (I), wherein R, R.sub.0 R.sub.1-R.sub.8, n, X, Y, Y.sup.1, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

##STR00001##

Disclosed are compounds, for example, compounds of formula (I), wherein R, R.sub.0 R.sub.1-R.sub.8, n, X, Y, Y.sup.1, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

##STR00001##

The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABA.sub.B receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABA.sub.B receptor agonist.

The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABA.sub.B receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABA.sub.B receptor agonist.

Disclosed herein is a long acting pharmaceutical composition for treating or preventing human immunodeficiency virus (HIV) infection. The pharmaceutical composition comprises a suspension of a lysine-based aspartyl protease inhibitor or salt thereof, a surface modifier, and a pharmaceutically acceptable carrier; wherein the lysine-based aspartyl protease inhibitor or salt thereof has an average effective particle size of less than about 500 nm. A method for treating or preventing HIV infection with the pharmaceutical composition is also disclosed.